FDA approves Boehringer Ingelheim MICARDIS
The FDA approves Boehringer Ingelheim’s MICARDIS® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors. This new indication is based on The ONTARGET Trial results which showed that MICARDIS® may prevent one in five serious CV events or death from cardiac causes.
- FDA Approves Expansion of Endologix’s Main Product Line
- FDA approves Multaq for heart rhythm disorders
- FDA approves Effient for thrombotic cardiovascular
- FDA approves market launch of Boston Scientific’s DES
